Circle CVI Announces FDA Clearance for cvi42 | Plaque
Circle Cardiovascular Imaging Inc. announced FDA clearance for cvi42 | Plaque, an AI-enabled solution for coronary artery disease evaluation.
"The clearance of cvi42 | Plaque marks a significant advancement for cardiology departments and imaging centers," stated Erkan Akyuz, CEO of Circle CVI.
This innovative solution allows clinicians to perform comprehensive coronary plaque analysis on-premise, enhancing diagnostic workflows and patient care.
- Fast, accurate, and reproducible results for quantifying total, calcified, and non-calcified plaque
- Secure, on-premise solution for greater control over patient data
- Improved study processing times and enhanced workflow efficiency
Author's summary: Circle CVI receives FDA clearance for cvi42 | Plaque.
More News
- Optical vendor Ribbon suffers ‘cybersecurity incident’
- Rejuvenating Rural Local Bodies through Effective Implementation of Jal Jeevan Mission
- JD Vance and Erika Kirk’s on-stage hug goes viral amid faith and controversy debate | The Express Tribune
- Why is the Google Doodle Pac-Man themed? | LBC
- The Source Magazine Remembers MF DOOM Five Years Later
- Cineworld announces luxury upgrade at Silverburn with new recliner seats
- Florence + The Machine - Everybody Scream Review
- When skeletons come out of the closet and onto the street - Washington Square News
- 10 tracks that prove MF DOOM was the master of samples
- Making KPop Demon Hunters sound magical meant finding the right harmonies